The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

In April, the CDC’s influential Advisory Committee on Immunization Practices recommended expanding RSV vaccination to ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Studies have found important benefits from the new RSV immunization and enhanced versions of the flu shot. Plus, the shingles ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...